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The incremental risk of coronary bypass surgery was
analyzed in 718 patients undergoing mitral valve re-
placement between 1971 and 1983. Ninety-eight patients
(14%) had significant coronary artery disease requiring
coronary bypass surgery. In 70 of these patients, the
originofthe mitral valvediseasewasnonischemic, whereas
28 patients had ischemic mitral regurgitation unsuitable
for conservative valve surgery.
There were six operative deaths (9%) and four peri-
operative myocardial infarctions (6%) after mitral valve
replacement and coronary bypass surgery for nonisch-
emic mitral valve disease. Operative mortality was re-
lated to low output cardiac failure before operation or
perioperative myocardial infarction. Actuarial curves
predict survival (± standard error) of 55 ± 7% at 5
years and 43 ± 8% at 10 years. Preoperative functional
Concomitant coronary artery disease has been reported to
be one of the most powerful determinants of early and late
mortality after mitral valve replacement (I). This has led to
the practice of combining coronary bypass surgery with
mitral valve replacement. Operative mortality for combined
mitral valve replacement and coronary bypass surgery ranges
from 3.5 (2) to 18% (3), the great variability reflecting the
different origins of the valvular lesion (4,5).
There is little information on late survival after combined
mitral valve replacement and coronary bypass surgery. We
present a 10 year follow-up study of patients who underwent
combined mitral valve replacement and coronary bypass
surgery for nonischemic mitral valve disease. The survival
data are compared with those of patients who underwent
mitral valve replacement alone (6) and those who had com-
bined mitral valve replacement and coronary bypass surgery
for ischemic mitral valve disease (7).
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class was the only significant predictor of long-term sur-
vival in this group (p < 0.05).
The actuarial survival of the 620 patients without
coronary artery disease who underwent mitral valve re-
placement alone was 63 ± 3% at 10 years. This was
significantly better than that of the 70 patients who
underwent mitral valve replacement and coronary by-
pass surgery for nonischemic mitral valve disease (p <
0.001). Conversely, 5 year survival of the 28 patients
with ischemic mitral regurgitation was 43 ± 10%. This
confirms the negative detrimental effect of an ischemic
origin of mitral valve disease on survival after mitral
valve replacement and coronary bypass surgery (p <
0.0001).
(J Am Coli Cardiol 1985;5:29-33)
Methods
Patients. Between 1971 and 1983, mitral valve replace-
ment was performed in 718 patients. All patients underwent
cardiac catheterization before operation. Coronary arteri-
ography was performed in those older than 40 years of age.
Six hundred twenty patients without coronary artery dis-
ease underwent mitral valve replacement alone. The mean
age of these patients was 52 years (range 28 to 82) and the
male to female ratio was I: 2. Ninety-eight patients (14%)
had significant coronary artery disease (defined as > 50%
reduction in luminal diameter in at least one plane on biplane
cinearteriography) requiring coronary bypass surgery. The
origin of the mitral valve disease was rheumatic in 57 pa-
tients. degenerative in 13 patients and ischemic in 28 pa-
tients. The patients who underwent combined mitral valve
replacement and coronary bypass surgery are analyzed in
detail and grouped according to nonischemic and ischemic
etiology.
Nonischemic mitral valve disease with associated
coronary artery disease. The 70 patients in this group had
primary mitral valve disease requiring valve replacement
(Table I). It has been our policy to perform coronary bypass
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Table 1. Preoperative Clinical Characteristics of Patients Who
Underwent Mitral Valve Replacement and Coronary
Bypass Surgery
Nonischemic MVD Ischemic MVD
No. of patients 70 28
Male patients (%) 47 71
Mean age (yr) (range) 56 (42 to 77) 63 (41 to 80)
Presenting features (%)
Dyspnea 100 100
Angina 41 79
Acute MI 0 71
NYHA functional class (%)
II 16 0
ill 58 14
IV 26 86
Valve lesion (%)
Stenosis 32 0
Mixed 51 0
Regurgitation 17 100
Ml = myocardial infarction; MVD = mitral valve disease; NYHA
= New York Heart Association.
surgery on all suitable patients with additional significant
coronary artery disease. The mean age of the patients was
56 years (range 42 to 77), and 33 patients (47%) were male.
The main presenting feature in all patients was dyspnea.
Twenty-nine patients also complained of angina, seven of
whom had had a previous myocardial infarction. Twenty-
eight patients (40%) had a localized wall motion abnormality
on the left ventriculogram.
Sixty-three patients (90%) received a ball and cage pros-
thesis. Forty-one patients (59%) received a single bypass
graft, 17 (24%) received two grafts and 12 (17%) received
three grafts (Table 2). Before 1978, the operation was per-
formed using intermittent ischemic arrest at moderate hy-
pothermia. Thereafter, cold cardioplegic arrest was used for
myocardial protection in 13 patients.
Ischemic mitral valve disease. It has been our policy
to treat patients with mild or moderate ischemic mitral re-
gurgitation by coronary bypass surgery alone and, when this
was insufficient, to attempt to repair the valve (7). The 28
patients who underwent mitral valve replacement and coro-
nary bypass surgery in this group had severe ischemic mitral
regurgitation and valve disease unsuitable for valve repair.
The mean age was 63 years (range 41 to 80) and 20
patients were male (71%) (Table I). Twenty-four patients
(86%) were in New York Heart Association functional class
IV. All patients had had a previous myocardial infarction,
20 (71%) of which occurred within I month of surgery.
Eleven patients had a ruptured papillary muscle. six of whom
have been previously described in detail (8). Ten patients
were in cardiogenic shock.
Twenty-five patients (89%) received a ball and cage pros-
thesis. Twelve patients (43%) received two coronary artery
bypass grafts and 16 patients (57%) received three grafts
(Table 2).
Perioperative myocardial infarction. The possibility
of a perioperative myocardial infarction was evaluated in
all patients, diagnosis being made on the basis of the fol-
lowing variables: I) new Qwaves on the electrocardiogram,
greater than 0.04 second in duration and greater than 3 mm
in depth; 2) creatine kinase greater than 500 IV. with 10%
specific (MB) myocardial isoenzyme; and 3) autopsy evi-
dence of recent infarction.
Follow-up. All patients were followed up on a pro-
spective basis using a combination of questionnaires and
telephone contacts with both patients and referring physi-
cians. The current status of the patients, determined in Oc-
tober 1983, was 96% complete. The mean length of follow-
up (± standard deviation) was 6.2 ± 2 years for the group
with mitral valve replacement only, 3.5 ± 2 years for the
group with nonischemic mitral valve disease undergoing
both valve replacement and coronary bypass surgery and
3.5 ± 3 years for the group with ischemic mitral valve
disease undergoing both valve replacement and coronary
bypass surgery.
Statisticalanalysis. The data were analyzed in an HP/3000
computer (Hewlett Packard) using the Statistical Package
for Social Sciences (9). The actuarial method (10) was used
to calculate 5 and 10 year survival (± standard error).
Survival curves were compared by an approximate chi-square
method (9).
Table 2. Variables of Coronary Artery Disease Associated With
Mitral Valve Disease (MVD)
Previous myocardial infarction
Localized wall motion
abnormality (%)
No. of grafts (%)
I
2
3
Mean no. of grafts per patient
Nonischernic
MVD
10
40
59
24
17
1.6
Ischemic
MVD
100
100
o
43
57
2.6
Results
Operative mortality. The operative mortality in the 620
control patients who underwent mitral valve replacement
alone was 6%. There were six (9%) operative deaths in the
70 patients who had mitral valve replacement and coronary
bypass surgery for nonischemic mitral valve disease. Two
of these patients had preoperative low output cardiac failure
secondary to severe rheumatic mitral regurgitation, with
incidental coronary artery disease. Three patients died after
perioperative myocardial infarction. The sixth death oc-
curred in a 64 year old patient who bled profusely from
acute gastric erosions during the procedure and could not
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Figure 2. Effect of ischemic etiology of valve disease on survival
after combined mitral valve replacement and coronary bypass surgery.
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analysis of clinical, hemodynamic and coronary artery vari-
ables revealed that only preoperative functional class was a
significant predictor (p < 0.05) of 10 year survival (Fig.
3). Left ventricular segmental wall motion abnormality and
previous myocardial infarction may have had an effect
(p < 0.3), but this did not reach conventional levels of
statistical significance. Conversely. age, sex, year of op-
eration, presence of preoperative angina, type of valve le-
sion, the hemodynamic variables of pulmonary artery sys-
tolic and wedge pressures, left ventricular end-diastolic
pressure, cardiac index, ejection fraction and the extent of
coronary artery disease did not have a significant effect.
In the patients with nonischemic mitral valve disease,
the 5 year survival rate for patients who underwent mitral
valve replacement and coronary bypass surgery was 58 ± 8%
for patients with mitral stenosis or mixed valvular lesions
and also 58 ± 16% for the II patients with pure mitral
be weaned from cardiopulmonary bypass. Four patients (6%)
had a perioperative myocardial infarction; three of these
infarctions occurred in the era before the introduction of
cardioplegia and were fatal. Indeed, in the 13 patients pro-
tected by cold cardioplegic arrest, there were no deaths due
to cardiac causes and a single, nonfatal perioperative myo-
cardial infarction.
Four (14%) of the 28 patients who underwent mitral valve
replacement and coronary bypass surgery for ischemic mi-
tral valve disease died within I month of operation. The
death was associated with acute preoperative myocardial
infarction and cardiogenic shock in three patients and per-
ioperative myocardial infarction in one patient.
Late mortality. The 10 year actuarial survival for the
620 patients who underwent mitral valve replacement alone
was 63 ± 3%. There were 22 late deaths after mitral valve
replacement and coronary bypass surgery for nonischemic
mitral valve disease, corresponding to 3.6% per year. Four
(18%) of these deaths were myocardial in origin and another
four were prosthetic valve-related. Actuarial curves pre-
dicted a survival rate of 55 ± 7% at 5 years and 43 ± 8%
at 10 years. This was significantly worse than that of the
control group undergoing mitral valve replacement alone
(p < 0.001) (Fig. I).
Of the 24 operative survivors after mitral valve replace-
ment and coronary bypass surgery for ischemic mitral valve
disease, 9 patients died within the first year. All of these
deaths were myocardial in origin. The 5 year actuarial sur-
vival rate in this group was 43 ± 10% (Fig. 2). Thus, the
ischemic origin of the mitral valve disease has an important
negative effect on survival after mitral valve replacement
and coronary bypass surgery (p < 0.0001).
Factors affecting survival in patients with nonisch-
ernie mitral valve disease. In the 70 patients who under-
went combined mitral valve replacement and coronary by-
pass surgery for nonischemic mitral valve disease, a univariate
Figure 1. Effect of coronary bypass surgery (CBS) on 10 year
survival after mitral valve replacement (MVR).
Figure 3. Effect of preoperative functional class on survival after
combined mitral valve replacement and coronary bypass surgery
for nonischemic mitral valve disease.
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regurgitation. Within this group, the survival curves of pa-
tients with rheumatic and degenerative mitral valve disease
were also similar.
Current status of patients. At follow-up assessment,
the 42 patients who survived the combined mitral valve
replacement and coronary bypass surgery for nonischemic
mitral valve disease were all in functional class I or II with
regard to effort tolerance; no patients complained of residual
angina. This group includes 8 of the 21 patients who under-
went surgery more than 10 years ago. Six of these patients
had rheumatic mitral valve disease and two had degenerative
mitral regurgitation. Five of the patients had multivessel
disease and three patients single vessel disease. No patients
have undergone repeat cardiac catheterization, so data on
graft potency are not available.
Discussion
Incidence of combined valvular and coronary artery
disease. With the recent trend toward mitral valve replace-
ment in a more elderly population (I), the incidence of
coronary artery disease has increased in these patients. In
our series, 70 (10%) of 690 patients with nonischemic mitral
valve disease had concomitant coronary artery disease re-
quiring coronary bypass surgery. This is considerably lower
than the 43% reported by Miller et al. (5). However, in
their series, which also included patients with ischemic mi-
tral regurgitation, only 50% of the patients underwent coro-
nary arteriography. The 10% incidence rate of coronary
artery disease in our patients who had mitral valve replace-
ment is considerably less than that of 27% for patients
undergoing aortic valve replacement at the Oregon Health
Sciences University (II). This is partly an age-related phe-
nomenon, the mean age of patients who underwent com-
bined mitral valve replacement and coronary bypass surgery
being 56 years compared with 64 years for those who had
the combined aortic procedure, and partly a sex-related phe-
nomenon, 74% of the aortic group with valve replacement
being male compared with 47% for the group with mitral
valve replacement.
Fifty-nine patients (83%) with nonischemic mitral valve
disease had predominant mitral stenosis. In many cases, the
resulting small left ventricle had an adequate blood supply
despite an impaired coronary circulation. Indeed, only 29
(41%) of these patients with concomitant coronary artery
disease presented with angina. This lack of correlation be-
tween angina and coronary artery disease contradicts the
conclusion of Bonchek et al. (12) that "coronary arteri-
ography may be safely omitted before valve replacement in
many patients with no symptoms of ischemic heart disease
and no risk factors known to increase its significance". It
strengthens our policy of performing coronary arteriography
in all patients undergoing valve replacement (13).
Operative mortality. Historically, combined mitral valve
replacement and coronary bypass surgery has been associ-
ated with a high mortality rate (3). Karp (4) suggested that
the rate is high because combined mitral valve and coronary
artery disease produce a cardiomyopathy that is not revers-
ible by valve replacement and coronary bypass surgery. In
our series, the operative mortality rate was 9%. This is
toward the lower end of the 3.5 to 18% range quoted by
others (2-5). One of the main determinants of operative
mortality in our patients who underwent mitral valve re-
placement and coronary bypass surgery for nonischemic
mitral valve disease was perioperative myocardial infarc-
tion. This occurred in 6% of our patients, which is similar
to the incidence reported by other surgical groups (5,14)
and is seemingly related to techniques of myocardial
protection.
In those patients who underwent cold cardioplegic arrest,
there were no early cardiac deaths and a single, nonfatal,
perioperative myocardial infarction. Given the small num-
bers of patients involved, these data do not reach statistical
significance, but it is our belief that cold cardioplegic arrest
is the preferred method of myocardial protection for patients
undergoing combined valve replacement and coronary by-
pass surgery. Reed et al. (2), using cardioplegia in a more
recent time frame (1978 to 1981), were able to report a
3.5% operative mortality rate for 28 patients who underwent
combined mitral valve replacement and coronary bypass
surgery.
Late survival. There is little information on late survival
after the combined procedure. Miller et al. (5) reported a
53% 3 year survival for a mixed group of patients, including
those with ischemic and nonischemic valve disease. They
suggested that neither the presence of coronary artery dis-
ease nor the etiology of the valve lesion was important. Our
results, however, suggest that coronary artery disease is an
important variable in the survival of patients undergo-
ing mitral valve replacement for rheumatic and degenerative
mitral valve disease.
The patients undergoing mitral valve replacement for
ischemic mitral regurgitation were a select group of patients
whose valve was unsuitable for repair. They were older and
had more severe coronary artery disease and left ventricular
wall motion abnormalities than the patients undergoing mi-
tral valve replacement and coronary bypass surgery for non-
ischemic mitral valve disease (Tables I and 2). Our con-
servative approach for ischemic mitral regurgitation is similar
to that recommended by Kay et al. (15), who reported a
33% 2 year survival rate for patients with ischemic mitral
regurgitation requiring combined mitral valve replacement
and coronary bypass surgery. In our series, the 5 year sur-
vival rate of patients who had the combined procedures for
ischemic mitral valve disease was 43%. Thus, there was a
significant difference in survival between patients who
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underwent mitral valve replacement and coronary bypass
surgery for ischemic and nonischemic mitral valve disease.
Factors affecting survival in patients with nonisch-
ernie mitral valve disease. Preoperative functional class
was an important predictor of long-term survival in those
patients who underwent combined mitral valve replacement
and coronary bypass surgery for nonischernic mitral valve
disease. This did not appear to correlate with hemodynamic
variables. Thus, we were unable to correlate pulmonary
artery pressures or left ventricular end-diastolic pressure
with operative mortality or long-term survival. This was
partly due to the small number of patients involved and to
the fact that the patients with an operative or late death
could be divided into two groups representing extreme forms
of a spectrum of disease: those with severe valve disease
and incidental coronary artery disease and those with mod-
erate valve disease and severe coronary artery disease. The
latter combination proved deleterious since left ventricular
damage in the form of previous myocardial infarction and
segmental wall motion abnormality appeared to have a neg-
ative effect on 10 year survival. As the presence of coronary
artery disease appeared to exert a significant effect on sur-
vival after mitral valve replacement, it might have been
expected that the number of diseased coronary arteries would
also have had an effect. This did not prove to be the case,
which is in line with the long-term results of combined aortic
valve replacement and coronary bypass surgery (11,16).
The negative effect of concomitant coronary artery dis-
ease requiring coronary bypass surgery on long-term sur-
vival after mitral valve replacement suggests either the pres-
ence of some permanent myocardial damage before operation,
or its relentless advance, which was not reversed by myo-
cardial revascularization. In the present climate of medical
opinion, particularly with the success of coronary bypass
surgery, it is unlikely that the question of whether diseased
coronary arteries should be bypassed at the time of valve
replacement will ever be answered formally by a prospective
trial. Bonow et al. (17) attempted to justify the use of valve
replacement alone in patients with both aortic valve disease
and coronary artery disease, but were heavily criticized by
Kirklin and Kouchoukos (18) for the small number of pa-
tients involved and the omission from the premise of patients
with left main stem disease,
Conclusions. I) Concomitant coronary artery disease
requiring coronary bypass surgery is an important variable
in the long-term survival of patients undergoing mitral valve
replacement of nonischemic mitral valve disease. 2) Patients
with ischemic mitral regurgitation unsuitable for treatment
by valve-conserving measures who require mitral valve re-
placement have a diminished chance of survival compared
with patients undergoing combined mitral valve replacement
and coronary bypass surgery for nonischemic mitral valve
disease.
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